JP2007505888A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007505888A5 JP2007505888A5 JP2006526721A JP2006526721A JP2007505888A5 JP 2007505888 A5 JP2007505888 A5 JP 2007505888A5 JP 2006526721 A JP2006526721 A JP 2006526721A JP 2006526721 A JP2006526721 A JP 2006526721A JP 2007505888 A5 JP2007505888 A5 JP 2007505888A5
- Authority
- JP
- Japan
- Prior art keywords
- triazol
- methoxypyridin
- methyl
- pyrazine
- pyridine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 24
- -1 3 ′, 5′-bis-trifluoromethylbiphenyl-4-yl Chemical group 0.000 claims 16
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 13
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 2
- QHESCAMHVWJIJA-UHFFFAOYSA-N 2-(2,3-dimethylphenyl)-5-[4-(6-methoxypyridin-3-yl)-5-methyl-1,2,4-triazol-3-yl]pyrazine Chemical compound C1=NC(OC)=CC=C1N1C(C=2N=CC(=NC=2)C=2C(=C(C)C=CC=2)C)=NN=C1C QHESCAMHVWJIJA-UHFFFAOYSA-N 0.000 claims 2
- PFIGDGJSZCKKLC-UHFFFAOYSA-N 2-(2,3-dimethylphenyl)-5-[5-(methoxymethyl)-4-(6-methoxypyridin-3-yl)-1,2,4-triazol-3-yl]pyrazine Chemical compound C=1C=C(OC)N=CC=1N1C(COC)=NN=C1C(N=C1)=CN=C1C1=CC=CC(C)=C1C PFIGDGJSZCKKLC-UHFFFAOYSA-N 0.000 claims 2
- ZSIWQFWQNSLVMF-UHFFFAOYSA-N 2-(2,3-dimethylphenyl)-5-[5-(methoxymethyl)-4-(6-methoxypyridin-3-yl)-1,2,4-triazol-3-yl]pyridine Chemical compound C=1C=C(OC)N=CC=1N1C(COC)=NN=C1C(C=N1)=CC=C1C1=CC=CC(C)=C1C ZSIWQFWQNSLVMF-UHFFFAOYSA-N 0.000 claims 2
- WIGMUHOLXOUURZ-UHFFFAOYSA-N 2-(2-fluoro-5-methoxyphenyl)-5-[4-(6-methoxypyridin-3-yl)-5-methyl-1,2,4-triazol-3-yl]pyrazine Chemical compound COC1=CC=C(F)C(C=2N=CC(=NC=2)C=2N(C(C)=NN=2)C=2C=NC(OC)=CC=2)=C1 WIGMUHOLXOUURZ-UHFFFAOYSA-N 0.000 claims 2
- APSMOISCLRKHCL-UHFFFAOYSA-N 2-(3-fluoro-2-methoxyphenyl)-5-[5-(methoxymethyl)-4-(6-methoxypyridin-3-yl)-1,2,4-triazol-3-yl]pyrazine Chemical compound C=1C=C(OC)N=CC=1N1C(COC)=NN=C1C(N=C1)=CN=C1C1=CC=CC(F)=C1OC APSMOISCLRKHCL-UHFFFAOYSA-N 0.000 claims 2
- JSWNOVXSWSYLDJ-UHFFFAOYSA-N 2-(4-fluoro-2-methylphenyl)-5-[5-(methoxymethyl)-4-(6-methoxypyridin-3-yl)-1,2,4-triazol-3-yl]pyrazine Chemical compound C=1C=C(OC)N=CC=1N1C(COC)=NN=C1C(N=C1)=CN=C1C1=CC=C(F)C=C1C JSWNOVXSWSYLDJ-UHFFFAOYSA-N 0.000 claims 2
- OFTJGQHJFQERAX-UHFFFAOYSA-N 2-(4-fluoro-2-methylphenyl)-5-[5-(methoxymethyl)-4-(6-methoxypyridin-3-yl)-1,2,4-triazol-3-yl]pyridine Chemical compound C=1C=C(OC)N=CC=1N1C(COC)=NN=C1C(C=N1)=CC=C1C1=CC=C(F)C=C1C OFTJGQHJFQERAX-UHFFFAOYSA-N 0.000 claims 2
- RKXQKJLVQGRIDP-UHFFFAOYSA-N 2-(5-fluoro-2-methoxyphenyl)-5-[4-(6-methoxypyridin-3-yl)-5-methyl-1,2,4-triazol-3-yl]pyrazine Chemical compound C1=NC(OC)=CC=C1N1C(C=2N=CC(=NC=2)C=2C(=CC=C(F)C=2)OC)=NN=C1C RKXQKJLVQGRIDP-UHFFFAOYSA-N 0.000 claims 2
- UWVQTFRVRSCGAZ-UHFFFAOYSA-N 2-(5-fluoro-2-methoxyphenyl)-5-[5-(methoxymethyl)-4-(6-methoxypyridin-3-yl)-1,2,4-triazol-3-yl]pyridine Chemical compound C=1C=C(OC)N=CC=1N1C(COC)=NN=C1C(C=N1)=CC=C1C1=CC(F)=CC=C1OC UWVQTFRVRSCGAZ-UHFFFAOYSA-N 0.000 claims 2
- YHKZSUNEWODEEO-UHFFFAOYSA-N 4-[5-[4-(6-methoxypyridin-3-yl)-5-methyl-1,2,4-triazol-3-yl]pyrazin-2-yl]-3-methylbenzonitrile Chemical compound C1=NC(OC)=CC=C1N1C(C=2N=CC(=NC=2)C=2C(=CC(=CC=2)C#N)C)=NN=C1C YHKZSUNEWODEEO-UHFFFAOYSA-N 0.000 claims 2
- YROLZLACGLYWCR-UHFFFAOYSA-N 4-[5-[5-(methoxymethyl)-4-(6-methoxypyridin-3-yl)-1,2,4-triazol-3-yl]pyrazin-2-yl]-3-methylbenzonitrile Chemical compound C=1C=C(OC)N=CC=1N1C(COC)=NN=C1C(N=C1)=CN=C1C1=CC=C(C#N)C=C1C YROLZLACGLYWCR-UHFFFAOYSA-N 0.000 claims 2
- AUIGHINKBLJVFJ-UHFFFAOYSA-N 4-[6-[5-(methoxymethyl)-4-(6-methoxypyridin-3-yl)-1,2,4-triazol-3-yl]pyridin-3-yl]-3-methylbenzonitrile Chemical compound C=1C=C(OC)N=CC=1N1C(COC)=NN=C1C(N=C1)=CC=C1C1=CC=C(C#N)C=C1C AUIGHINKBLJVFJ-UHFFFAOYSA-N 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 150000001204 N-oxides Chemical class 0.000 claims 2
- 208000027520 Somatoform disease Diseases 0.000 claims 2
- 230000009286 beneficial effect Effects 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 208000027753 pain disease Diseases 0.000 claims 2
- 206010036596 premature ejaculation Diseases 0.000 claims 2
- 230000001568 sexual effect Effects 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- UAFXQKAEBVQYOV-UHFFFAOYSA-N 2-(2,3-dimethylphenyl)-5-[5-(2-methoxyethoxymethyl)-4-(6-methoxypyridin-3-yl)-1,2,4-triazol-3-yl]pyridine Chemical compound C=1C=C(OC)N=CC=1N1C(COCCOC)=NN=C1C(C=N1)=CC=C1C1=CC=CC(C)=C1C UAFXQKAEBVQYOV-UHFFFAOYSA-N 0.000 claims 1
- XINJMEAAYQRXSR-UHFFFAOYSA-N 2-(2,5-dichlorophenyl)-5-[4-(6-methoxypyridin-3-yl)-5-methyl-1,2,4-triazol-3-yl]pyrazine Chemical compound C1=NC(OC)=CC=C1N1C(C=2N=CC(=NC=2)C=2C(=CC=C(Cl)C=2)Cl)=NN=C1C XINJMEAAYQRXSR-UHFFFAOYSA-N 0.000 claims 1
- GGOXARLGSJCOCE-UHFFFAOYSA-N 2-(2,5-difluorophenyl)-5-[4-(6-methoxypyridin-3-yl)-5-methyl-1,2,4-triazol-3-yl]pyrazine Chemical compound C1=NC(OC)=CC=C1N1C(C=2N=CC(=NC=2)C=2C(=CC=C(F)C=2)F)=NN=C1C GGOXARLGSJCOCE-UHFFFAOYSA-N 0.000 claims 1
- ATCWCKFDKDUYOB-UHFFFAOYSA-N 2-(2,5-dimethoxyphenyl)-5-[5-(2-methoxyethoxymethyl)-4-(6-methoxypyridin-3-yl)-1,2,4-triazol-3-yl]pyridine Chemical compound C=1C=C(OC)N=CC=1N1C(COCCOC)=NN=C1C(C=N1)=CC=C1C1=CC(OC)=CC=C1OC ATCWCKFDKDUYOB-UHFFFAOYSA-N 0.000 claims 1
- PQBHDRYNKOBISG-UHFFFAOYSA-N 2-(2,5-dimethylphenyl)-5-[4-(6-methoxypyridin-3-yl)-5-methyl-1,2,4-triazol-3-yl]pyrazine Chemical compound C1=NC(OC)=CC=C1N1C(C=2N=CC(=NC=2)C=2C(=CC=C(C)C=2)C)=NN=C1C PQBHDRYNKOBISG-UHFFFAOYSA-N 0.000 claims 1
- MJCPNVXKUHWJCV-UHFFFAOYSA-N 2-(2-fluoro-3-methoxyphenyl)-5-[5-(2-methoxyethoxymethyl)-4-(6-methoxypyridin-3-yl)-1,2,4-triazol-3-yl]pyridine Chemical compound C=1C=C(OC)N=CC=1N1C(COCCOC)=NN=C1C(C=N1)=CC=C1C1=CC=CC(OC)=C1F MJCPNVXKUHWJCV-UHFFFAOYSA-N 0.000 claims 1
- MVGKHXFWRLSMDA-UHFFFAOYSA-N 2-(2-fluoro-5-methylphenyl)-5-[4-(6-methoxypyridin-3-yl)-5-methyl-1,2,4-triazol-3-yl]pyrazine Chemical compound C1=NC(OC)=CC=C1N1C(C=2N=CC(=NC=2)C=2C(=CC=C(C)C=2)F)=NN=C1C MVGKHXFWRLSMDA-UHFFFAOYSA-N 0.000 claims 1
- IYGZCKOFXIUPJK-UHFFFAOYSA-N 2-(3,5-difluorophenyl)-5-[4-(6-methoxypyridin-3-yl)-5-methyl-1,2,4-triazol-3-yl]pyrazine Chemical compound C1=NC(OC)=CC=C1N1C(C=2N=CC(=NC=2)C=2C=C(F)C=C(F)C=2)=NN=C1C IYGZCKOFXIUPJK-UHFFFAOYSA-N 0.000 claims 1
- XYAMCELLHQCEOZ-UHFFFAOYSA-N 2-(3,5-difluorophenyl)-5-[5-(2-methoxyethoxymethyl)-4-(6-methoxypyridin-3-yl)-1,2,4-triazol-3-yl]pyridine Chemical compound C=1C=C(OC)N=CC=1N1C(COCCOC)=NN=C1C(C=N1)=CC=C1C1=CC(F)=CC(F)=C1 XYAMCELLHQCEOZ-UHFFFAOYSA-N 0.000 claims 1
- RJXNJUYVKGIPOL-UHFFFAOYSA-N 2-(3,5-dimethylphenyl)-5-[4-(6-methoxypyridin-3-yl)-5-methyl-1,2,4-triazol-3-yl]pyrazine Chemical compound C1=NC(OC)=CC=C1N1C(C=2N=CC(=NC=2)C=2C=C(C)C=C(C)C=2)=NN=C1C RJXNJUYVKGIPOL-UHFFFAOYSA-N 0.000 claims 1
- BTAXYWQUOQEEEL-UHFFFAOYSA-N 2-(3-chloro-4-fluorophenyl)-5-[5-(2-methoxyethoxymethyl)-4-(6-methoxypyridin-3-yl)-1,2,4-triazol-3-yl]pyridine Chemical compound C=1C=C(OC)N=CC=1N1C(COCCOC)=NN=C1C(C=N1)=CC=C1C1=CC=C(F)C(Cl)=C1 BTAXYWQUOQEEEL-UHFFFAOYSA-N 0.000 claims 1
- HWPDYNZUAISOPP-UHFFFAOYSA-N 2-(3-fluoro-2-methoxyphenyl)-5-[4-(6-methoxypyridin-3-yl)-5-methyl-1,2,4-triazol-3-yl]pyrazine Chemical compound C1=NC(OC)=CC=C1N1C(C=2N=CC(=NC=2)C=2C(=C(F)C=CC=2)OC)=NN=C1C HWPDYNZUAISOPP-UHFFFAOYSA-N 0.000 claims 1
- MOUKSDZKDKSZOM-UHFFFAOYSA-N 2-(4-fluoro-2-methoxyphenyl)-5-[5-(2-methoxyethoxymethyl)-4-(6-methoxypyridin-3-yl)-1,2,4-triazol-3-yl]pyridine Chemical compound C=1C=C(OC)N=CC=1N1C(COCCOC)=NN=C1C(C=N1)=CC=C1C1=CC=C(F)C=C1OC MOUKSDZKDKSZOM-UHFFFAOYSA-N 0.000 claims 1
- JTBHLQXMGZKKRH-UHFFFAOYSA-N 2-(4-fluoro-2-methylphenyl)-5-[4-(6-methoxypyridin-3-yl)-5-methyl-1,2,4-triazol-3-yl]pyrazine Chemical compound C1=NC(OC)=CC=C1N1C(C=2N=CC(=NC=2)C=2C(=CC(F)=CC=2)C)=NN=C1C JTBHLQXMGZKKRH-UHFFFAOYSA-N 0.000 claims 1
- ROTIMSQHRRTBTC-UHFFFAOYSA-N 2-(5-chloro-2-methoxyphenyl)-5-[5-(2-methoxyethoxymethyl)-4-(6-methoxypyridin-3-yl)-1,2,4-triazol-3-yl]pyridine Chemical compound C=1C=C(OC)N=CC=1N1C(COCCOC)=NN=C1C(C=N1)=CC=C1C1=CC(Cl)=CC=C1OC ROTIMSQHRRTBTC-UHFFFAOYSA-N 0.000 claims 1
- MUGLLHSLWLZTNO-UHFFFAOYSA-N 2-(5-fluoro-2-methoxyphenyl)-5-[5-(2-methoxyethoxymethyl)-4-(6-methoxypyridin-3-yl)-1,2,4-triazol-3-yl]pyridine Chemical compound C=1C=C(OC)N=CC=1N1C(COCCOC)=NN=C1C(C=N1)=CC=C1C1=CC(F)=CC=C1OC MUGLLHSLWLZTNO-UHFFFAOYSA-N 0.000 claims 1
- CPGGWTDWVBRKBV-UHFFFAOYSA-N 2-(5-fluoro-2-methylphenyl)-5-[5-(2-methoxyethoxymethyl)-4-(6-methoxypyridin-3-yl)-1,2,4-triazol-3-yl]pyridine Chemical compound C=1C=C(OC)N=CC=1N1C(COCCOC)=NN=C1C(C=N1)=CC=C1C1=CC(F)=CC=C1C CPGGWTDWVBRKBV-UHFFFAOYSA-N 0.000 claims 1
- QPCQXRPGMYIZQS-UHFFFAOYSA-N 2-methoxy-5-[3-(2-methoxyethoxymethyl)-5-[6-(2-methoxy-5-methylphenyl)pyridin-3-yl]-1,2,4-triazol-4-yl]pyridine Chemical compound C=1C=C(OC)N=CC=1N1C(COCCOC)=NN=C1C(C=N1)=CC=C1C1=CC(C)=CC=C1OC QPCQXRPGMYIZQS-UHFFFAOYSA-N 0.000 claims 1
- IAWIOJCDFAYWHC-UHFFFAOYSA-N 3-[4-(3,5-dichlorophenyl)phenyl]-4-(2-methoxyphenyl)-5-methyl-1,2,4-triazole Chemical compound COC1=CC=CC=C1N1C(C=2C=CC(=CC=2)C=2C=C(Cl)C=C(Cl)C=2)=NN=C1C IAWIOJCDFAYWHC-UHFFFAOYSA-N 0.000 claims 1
- RFWMFPSOKLXYET-UHFFFAOYSA-N 3-[4-[3,5-bis(trifluoromethyl)phenyl]phenyl]-4-(2-fluorophenyl)-5-methyl-1,2,4-triazole Chemical compound C=1C=CC=C(F)C=1N1C(C)=NN=C1C(C=C1)=CC=C1C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 RFWMFPSOKLXYET-UHFFFAOYSA-N 0.000 claims 1
- MDKZAZZFTZGHJP-UHFFFAOYSA-N 3-ethyl-5-(4-imidazol-1-ylphenyl)-4-(4-methoxyphenyl)-1,2,4-triazole Chemical compound C=1C=C(OC)C=CC=1N1C(CC)=NN=C1C(C=C1)=CC=C1N1C=CN=C1 MDKZAZZFTZGHJP-UHFFFAOYSA-N 0.000 claims 1
- WWCKNCVBSIWKGU-UHFFFAOYSA-N 5-(2,3-dimethylphenyl)-2-[5-(methoxymethyl)-4-(6-methoxypyridin-3-yl)-1,2,4-triazol-3-yl]pyridine Chemical compound C=1C=C(OC)N=CC=1N1C(COC)=NN=C1C(N=C1)=CC=C1C1=CC=CC(C)=C1C WWCKNCVBSIWKGU-UHFFFAOYSA-N 0.000 claims 1
- RCQOQEWBNAKEGY-UHFFFAOYSA-N 5-(4-fluoro-2-methylphenyl)-2-[5-(methoxymethyl)-4-(6-methoxypyridin-3-yl)-1,2,4-triazol-3-yl]pyridine Chemical compound C=1C=C(OC)N=CC=1N1C(COC)=NN=C1C(N=C1)=CC=C1C1=CC=C(F)C=C1C RCQOQEWBNAKEGY-UHFFFAOYSA-N 0.000 claims 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 1
- 208000027559 Appetite disease Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000005171 Dysmenorrhea Diseases 0.000 claims 1
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 206010057671 Female sexual dysfunction Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010057672 Male sexual dysfunction Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 claims 1
- 101800000989 Oxytocin Proteins 0.000 claims 1
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 claims 1
- 208000005107 Premature Birth Diseases 0.000 claims 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 claims 1
- 206010036590 Premature baby Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 1
- 208000037849 arterial hypertension Diseases 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 claims 1
- 229960001723 oxytocin Drugs 0.000 claims 1
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical group [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 150000003852 triazoles Chemical class 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0322159A GB0322159D0 (en) | 2003-09-22 | 2003-09-22 | New substituted triazoles for use as novel pharmaceuticals |
| GB0403150A GB0403150D0 (en) | 2004-02-12 | 2004-02-12 | Novel pharmaceuticals |
| GB0415110A GB0415110D0 (en) | 2004-07-05 | 2004-07-05 | Substituted triazole derivatives as oxytocin antagonists |
| PCT/IB2004/002977 WO2005028452A1 (en) | 2003-09-22 | 2004-09-10 | Substituted triazole derivatives as oxytocin antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007505888A JP2007505888A (ja) | 2007-03-15 |
| JP2007505888A5 true JP2007505888A5 (enExample) | 2007-10-25 |
Family
ID=34381637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006526721A Pending JP2007505888A (ja) | 2003-09-22 | 2004-09-10 | オキシトシン拮抗薬としての置換トリアゾール誘導体 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1673355A1 (enExample) |
| JP (1) | JP2007505888A (enExample) |
| AR (1) | AR045791A1 (enExample) |
| BR (1) | BRPI0414663A (enExample) |
| CA (1) | CA2539297C (enExample) |
| MX (1) | MXPA06003158A (enExample) |
| NL (1) | NL1027084C2 (enExample) |
| PA (1) | PA8613001A1 (enExample) |
| PE (1) | PE20050950A1 (enExample) |
| TW (1) | TW200526606A (enExample) |
| UY (1) | UY28524A1 (enExample) |
| WO (1) | WO2005028452A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7745630B2 (en) | 2003-12-22 | 2010-06-29 | Justin Stephen Bryans | Triazolyl piperidine arginine vasopressin receptor modulators |
| ES2594874T3 (es) * | 2004-11-18 | 2016-12-23 | Synta Pharmaceuticals Corp. | Compuestos de triazol que modulan la actividad de HSP90 |
| AP2007004047A0 (en) | 2005-01-20 | 2007-06-30 | Pfizer Ltd | Substituted triazole derivatives as oxtocin antagonists |
| WO2006100557A1 (en) * | 2005-03-21 | 2006-09-28 | Pfizer Limited | Substituted triazole derivatives as oxytocin antagonists |
| WO2006100588A1 (en) * | 2005-03-21 | 2006-09-28 | Pfizer Limited | Substituted triazole derivatives as oxytocin antagonists |
| EP2305674A1 (en) | 2005-07-09 | 2011-04-06 | AstraZeneca AB | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes |
| WO2007017752A1 (en) * | 2005-08-10 | 2007-02-15 | Pfizer Limited | Substituted triazole derivatives as oxytocin antagonists |
| FR2903985B1 (fr) | 2006-07-24 | 2008-09-05 | Sanofi Aventis Sa | Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
| FR2904316B1 (fr) | 2006-07-31 | 2008-09-05 | Sanofi Aventis Sa | Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique. |
| DE102006059710A1 (de) * | 2006-12-18 | 2008-06-19 | Freie Universität Berlin | Substituierte 4-Hydroxypyridine |
| FR2910473B1 (fr) | 2006-12-26 | 2009-02-13 | Sanofi Aventis Sa | Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique. |
| NZ592297A (en) | 2008-09-22 | 2012-11-30 | Cayman Chemical Co Inc | 2-Aryl-5-heteroaryl pyridine and pyrimidine derivatives as pharmaceutical active agents |
| ES2716862T3 (es) | 2014-12-22 | 2019-06-17 | Ferring Bv | Terapia con antagonistas del receptor de oxitocina en la fase lútea para la implantación y embarazo en mujeres que se someten a tecnologías de reproducción asistida |
| JP2020502211A (ja) | 2016-12-21 | 2020-01-23 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 縮合環基を有するアザシクロブチルトリアゾール誘導体、その製造方法および医薬におけるその使用 |
| TW201823231A (zh) | 2016-12-28 | 2018-07-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 氮雜雙環基取代的三唑類衍生物、其製備方法及其在醫藥上的應用 |
| WO2019242642A1 (zh) * | 2018-06-20 | 2019-12-26 | 江苏恒瑞医药股份有限公司 | 一种otr抑制剂的可药用盐、晶型及制备方法 |
| CN113004250B (zh) * | 2019-12-19 | 2022-07-26 | 上海森辉医药有限公司 | 一种制备取代的三唑衍生物的方法 |
| JP2022042278A (ja) * | 2020-09-02 | 2022-03-14 | 国立大学法人浜松医科大学 | 化合物又はその塩及び中枢オキシトシン受容体イメージング剤 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000063363A (ja) * | 1998-08-12 | 2000-02-29 | Yamanouchi Pharmaceut Co Ltd | 新規なトリアゾール誘導体 |
| WO2001058880A1 (en) * | 2000-02-08 | 2001-08-16 | Yamanouchi Pharmaceutical Co., Ltd. | Novel triazole derivatives |
| WO2001087855A1 (en) * | 2000-05-19 | 2001-11-22 | Yamanouchi Pharmaceutical Co., Ltd. | Triazole derivatives |
| ATE297913T1 (de) * | 2001-07-05 | 2005-07-15 | Pfizer Prod Inc | Sulfonyl-heteroaryl-triazole als entzündungshemmende und analgetische mittel |
| DK1458381T3 (da) * | 2001-12-20 | 2006-03-20 | Applied Research Systems | Triazoler som oxytocinantagonister |
-
2004
- 2004-09-10 MX MXPA06003158A patent/MXPA06003158A/es active IP Right Grant
- 2004-09-10 CA CA2539297A patent/CA2539297C/en not_active Expired - Fee Related
- 2004-09-10 EP EP04769366A patent/EP1673355A1/en not_active Withdrawn
- 2004-09-10 WO PCT/IB2004/002977 patent/WO2005028452A1/en not_active Ceased
- 2004-09-10 BR BRPI0414663-8A patent/BRPI0414663A/pt not_active IP Right Cessation
- 2004-09-10 JP JP2006526721A patent/JP2007505888A/ja active Pending
- 2004-09-20 PE PE2004000912A patent/PE20050950A1/es not_active Application Discontinuation
- 2004-09-20 UY UY28524A patent/UY28524A1/es not_active Application Discontinuation
- 2004-09-21 TW TW093128603A patent/TW200526606A/zh unknown
- 2004-09-21 AR ARP040103392A patent/AR045791A1/es unknown
- 2004-09-21 PA PA20048613001A patent/PA8613001A1/es unknown
- 2004-09-22 NL NL1027084A patent/NL1027084C2/nl not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007505888A5 (enExample) | ||
| CA2539297A1 (en) | Substituted triazole derivatives as oxytocin antagonists | |
| AU2006284666B2 (en) | Substituted benzimidazoles and methods of preparation | |
| TWI423962B (zh) | 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物 | |
| AU2002341921B8 (en) | Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5 | |
| CN103121996B (zh) | 用作mek抑制剂的杂芳基取代的芳基氨基吡啶衍生物 | |
| JP2007524696A5 (enExample) | ||
| CA2595569A1 (en) | Substituted triazole derivatives as oxytocin antagonists | |
| JP2007519735A5 (enExample) | ||
| TW200302222A (en) | Novel 1, 2, 4-triazole compounds | |
| MX2014015350A (es) | Compuestos de triazolona como inhibidores de mpegs-1. | |
| JP2010505809A5 (enExample) | ||
| JP2006500348A5 (enExample) | ||
| KR20010083055A (ko) | 글리코겐 신타제 키나제 3의 억제제 | |
| WO2005063738A1 (ja) | 新規２－へテロアリール置換ベンズイミダゾール誘導体 | |
| JP2005527625A5 (enExample) | ||
| AU2001295026A1 (en) | Inhibitors of glycogen synthase kinase 3 | |
| EP1317433A2 (en) | Inhibitors of glycogen synthase kinase 3 | |
| EP1957478A2 (en) | New compounds | |
| JP2007508346A5 (enExample) | ||
| CA2736955A1 (en) | Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
| RU2149872C1 (ru) | Пиридилтиосоединения для борьбы с бактериями helicobacter | |
| AU2002247726B2 (en) | 2-thio-substituted imidazole derivatives and the use thereof in the pharmaceutical industry | |
| WO2007037543A9 (ja) | ビアリールアミド誘導体 | |
| AU2014244855A1 (en) | Pyrazole derivative |